Taiko Pharmaceutical Gains Most Since Listing on Drug-Resistant Bacteria

Taiko Pharmaceutical Co., a Japanese maker of antiseptics, rose the most since listing on the Tokyo Stock Exchange after several types of drug-resistant bacteria were reportedly found in the country.

The stock surged 29 percent to 1,336 yen as of 1:26 p.m. on the exchange, the biggest gain since March 2009. Taiko has fallen 30 percent this year, compared with 7.8 percent decline in the benchmark Topix index.

Forty-six patients have been infected with a drug-resistant bacterium called Acinetobacter at Tokyo’s Teikyo University Hospital over the past year, the Yomiuri newspaper reported today. The report also said bacteria with the NDM-1 gene, resistant to almost all antibiotics, was identified for the first time in Japan yesterday in a patient at Dokkyo Medical University Hospital, north of Tokyo.

“The stock’s surge may be attributed to the new bacterium,” said Hitoshi Ohnishi, an analyst at Cosmo Securities Co., who has a “neutral plus” rating on Osaka-based Taiko. “I don’t know how effective their products are, but the company has an established reputation in the antibacterial business.”

To contact the reporter on this story: Masatsugu Horie in Osaka at mhorie3@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.